Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE study

Journal of Clinical Lipidology

Volumn 8, Issue 1, 2014, Pages 69-76

  Ito, Matthew K ^a   Maki, Kevin C ^b   Brinton, Eliot A ^c   Cohen, Jerome D ^d   Jacobson, Terry A ^e  

^a OREGON STATE UNIVERSITY   (United States)

^b Biofortis Clinical Research   (United States)

^c Utah Foundation for Biomedical Research   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P450; Discontinuation; Drug interactions; Muscle pain; Myopathy; OATP1B1; P glycoprotein; Statins

Indexed keywords

CYTOCHROME P450; DISCONTINUATION; DRUG INTERACTIONS; MUSCLE PAIN; MYOPATHY; OATP1B1; P-GLYCOPROTEIN; STATINS;

CYTOCHROME P-450 ENZYME SYSTEM; DEMOGRAPHY; FEMALE; HEALTH EDUCATION; HEALTH SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLES; MYALGIA; UNITED STATES;

EID: 84893933695     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.10.006     Document Type: Article

References (21)

1. M.K. Ito Dyslipidemia: management using optimal lipid-lowering therapy Ann Pharmacother 46 2012 1368 1381
2. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patient - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
3. J.D. Cohen, E.A. Brinton, M.K. Ito, and T.A. Jacobson Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 2012 208 215
4. M. Wei, M.K. Ito, J.D. Cohen, E.A. Brinton, and T.A. Jacobson Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education J Clin Lipidol 7 2013 472 483
5. A. Bakhai, U. Rigney, S. Hollis, and C. Emmas Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population Pharmacoepidemiol Drug Saf 21 2012 485 493
6. M.K. Ito Statin drug interactions in patients with comorbidities and on multiple medications US Endocrinol 8 2012 104 111
7. P.J. Neuvonen, M. Niemi, and J.T. Backman Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 80 2006 565 581
8. Epocrates. Available at: http://www.epocrates.com/. Accessed June 1, 2012.
9. The diabetes dilemma for statin users. New York Times. March 5, 2012. Available at: http://www.nytimes.com/2012/03/05/opinion/the-diabetes-dilemma- for-statinusers.html. Accessed March 21, 2013.
10. Y.H. Gomez Sandoval, M.V. Braganza, and S.S. Daskalopoulou Statin discontinuation in high-risk patients: a systematic review of the evidence Curr Pharm Des 17 2011 3669 3689
11. T.T. Abd, and T.A. Jacobson Statin-induced myopathy: a review and update Expert Opin Drug Saf 10 2011 373 387
12. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, C. Lenfant American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation 106 2002 1024 1028
13. D. Rosenbaum, J. Dallongeville, P. Sabouret, and E. Bruckert Discontinuation of statin therapy due to muscular side effects: a survey in real life Nutr Metab Cardiovasc Dis 23 2013 871 875
14. SEARCH Collaborative Group Link E., and S. Parish et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study N Engl J Med 359 2008 789 799
15. P.C. Santos, A.C. Gagliardi, and M.H. Miname et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia Eur J Clin Pharmacol 68 2012 273 279
16. J.Y. Chung, J.Y. Cho, and K.S. Yu et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers Clin Pharmacol Ther 78 2005 342 350
17. J.H. Choi, M.G. Lee, J.Y. Cho, J.E. Lee, K.H. Kim, and K. Park Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans Clin Pharmacol Ther 83 2008 251 257
18. K.R. Saverno, L.E. Hines, and T.L. Warholak et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions J Am Med Inform Assoc 18 2011 32 37
19. R. Lloret, J. Ycas, M. Stein, S. Haffner STARSHIP Study Group Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial) Am J Cardiol 98 2006 768 773
20. M.A. Albert, R.J. Glynn, and F.A. Fonseca et al. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial Am Heart J 162 2011 106 114
21. E. Lee, S. Ryan, and B. Birmingham et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Clin Pharmacol Ther 78 2005 330 341